Cite
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
MLA
Fausto Petrelli, et al. Comparative Efficacy of Palbociclib, Ribociclib and Abemaciclib for ER+ Metastatic Breast Cancer: An Adjusted Indirect Analysis of Randomized Controlled Trials. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7152397824d26a1562f0f39d91a50fe3&authtype=sso&custid=ns315887.
APA
Fausto Petrelli, Vito Amoroso, Karen Borgonovo, Mary Cabiddu, Alfredo Berruti, Rebecca Pedersini, Sandro Barni, Mara Ghilardi, Maria Chiara Parati, & Antonio Ghidini. (2019). Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Chicago
Fausto Petrelli, Vito Amoroso, Karen Borgonovo, Mary Cabiddu, Alfredo Berruti, Rebecca Pedersini, Sandro Barni, Mara Ghilardi, Maria Chiara Parati, and Antonio Ghidini. 2019. “Comparative Efficacy of Palbociclib, Ribociclib and Abemaciclib for ER+ Metastatic Breast Cancer: An Adjusted Indirect Analysis of Randomized Controlled Trials,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7152397824d26a1562f0f39d91a50fe3&authtype=sso&custid=ns315887.